FMR LLC 13D and 13G filings for Xenon Pharmaceuticals Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-03-07 10:01 am Purchase | 2025-02-28 | 13G | Xenon Pharmaceuticals Inc. XENE | FMR LLC | 7,851,098 10.300% | 983,414 (+14.32%) | Filing |
| 2024-11-12 10:40 am Purchase | 2024-11-08 | 13G | Xenon Pharmaceuticals Inc. XENE | FMR LLC | 6,867,684 9.064% | 1,211,762 (+21.42%) | Filing |
| 2024-02-09 10:05 am Purchase | 2024-02-08 | 13G | Xenon Pharmaceuticals Inc. XENE | FMR LLC | 5,655,922 7.556% | 965,093 (+20.57%) | Filing |
| 2023-02-09 12:46 pm Purchase | 2023-02-09 | 13G | Xenon Pharmaceuticals Inc. XENE | FMR LLC | 4,690,829 7.500% | 780,812 (+19.97%) | Filing |
| 2022-02-09 10:04 am Purchase | 2022-02-08 | 13G | Xenon Pharmaceuticals Inc. XENE | FMR LLC | 3,910,017 7.579% | 1,284,465 (+48.92%) | Filing |
| 2021-02-08 10:35 am Purchase | 2021-02-05 | 13G | Xenon Pharmaceuticals Inc. XENE | FMR LLC | 2,625,552 7.499% | 2,625,552 (New Position) | Filing |